PE20061446A1 - Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4 - Google Patents
Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4Info
- Publication number
- PE20061446A1 PE20061446A1 PE2006000543A PE2006000543A PE20061446A1 PE 20061446 A1 PE20061446 A1 PE 20061446A1 PE 2006000543 A PE2006000543 A PE 2006000543A PE 2006000543 A PE2006000543 A PE 2006000543A PE 20061446 A1 PE20061446 A1 PE 20061446A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- benzymidazole
- agonists
- receptors
- methyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- -1 2-ISOPROPYL-1H-BENZOIMIDAZOL-4-CARBONYL Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68446605P | 2005-05-25 | 2005-05-25 | |
| US68447805P | 2005-05-25 | 2005-05-25 | |
| US74841505P | 2005-12-08 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061446A1 true PE20061446A1 (es) | 2007-01-16 |
Family
ID=37452788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000543A PE20061446A1 (es) | 2005-05-25 | 2006-05-23 | Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4 |
Country Status (26)
| Country | Link |
|---|---|
| US (10) | US7759363B2 (enExample) |
| EP (1) | EP1899324B1 (enExample) |
| JP (2) | JP5072111B2 (enExample) |
| KR (1) | KR101333280B1 (enExample) |
| AR (1) | AR057327A1 (enExample) |
| AT (1) | ATE535523T1 (enExample) |
| AU (1) | AU2006250009B2 (enExample) |
| BR (1) | BRPI0611202C1 (enExample) |
| CA (1) | CA2607280C (enExample) |
| CY (1) | CY1112366T1 (enExample) |
| DK (1) | DK1899324T3 (enExample) |
| EA (1) | EA013240B1 (enExample) |
| ES (1) | ES2376115T3 (enExample) |
| HR (1) | HRP20120108T2 (enExample) |
| IL (1) | IL186883A (enExample) |
| MA (1) | MA29541B1 (enExample) |
| MX (1) | MX2007014762A (enExample) |
| MY (1) | MY147756A (enExample) |
| NO (1) | NO339658B1 (enExample) |
| NZ (1) | NZ563068A (enExample) |
| PE (1) | PE20061446A1 (enExample) |
| PL (1) | PL1899324T3 (enExample) |
| PT (1) | PT1899324E (enExample) |
| SI (1) | SI1899324T1 (enExample) |
| TW (1) | TWI388555B (enExample) |
| WO (1) | WO2006127815A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1664036T3 (pl) * | 2003-09-03 | 2012-04-30 | Pfizer | Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7256294B2 (en) * | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010111058A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| LT2419104T (lt) * | 2009-04-13 | 2018-02-12 | Theravance Biopharma R&D Ip, Llc | 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| US9676703B2 (en) | 2013-08-09 | 2017-06-13 | Santen Pharmaceutical Co., Ltd. | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| JPH111472A (ja) | 1996-04-30 | 1999-01-06 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体及びそれを含有する医薬組成物 |
| KR20010043032A (ko) | 1998-04-28 | 2001-05-25 | 도모따께 다께시 | 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체 |
| TR200101239T2 (tr) | 1998-11-03 | 2001-11-21 | Basf Aktiengesellschaft | İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları |
| US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
| JP2001122784A (ja) | 1999-10-27 | 2001-05-08 | Dainippon Pharmaceut Co Ltd | １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬 |
| US6552046B2 (en) * | 2000-06-07 | 2003-04-22 | Aryx Therapeutics | Materials and methods for the treatment of gastroesophageal reflux disease |
| US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| ES2285227T3 (es) | 2002-08-05 | 2007-11-16 | Eli Lilly And Company | Arilbenzodiazepinas sustituidas con piperazina. |
| WO2004026868A1 (en) * | 2002-09-20 | 2004-04-01 | Pfizer Japan Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
| JP2004277318A (ja) * | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物 |
| JP2004277320A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物 |
| PL1664036T3 (pl) | 2003-09-03 | 2012-04-30 | Pfizer | Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7256294B2 (en) | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
-
2006
- 2006-05-17 MY MYPI20062263A patent/MY147756A/en unknown
- 2006-05-22 TW TW095118168A patent/TWI388555B/zh not_active IP Right Cessation
- 2006-05-23 PE PE2006000543A patent/PE20061446A1/es active IP Right Grant
- 2006-05-24 BR BRPI0611202A patent/BRPI0611202C1/pt not_active IP Right Cessation
- 2006-05-24 SI SI200631257T patent/SI1899324T1/sl unknown
- 2006-05-24 US US11/439,671 patent/US7759363B2/en active Active
- 2006-05-24 AR ARP060102166A patent/AR057327A1/es active IP Right Grant
- 2006-05-24 KR KR1020077030010A patent/KR101333280B1/ko not_active Expired - Fee Related
- 2006-05-24 MX MX2007014762A patent/MX2007014762A/es active IP Right Grant
- 2006-05-24 PT PT06760341T patent/PT1899324E/pt unknown
- 2006-05-24 AT AT06760341T patent/ATE535523T1/de active
- 2006-05-24 DK DK06760341.5T patent/DK1899324T3/da active
- 2006-05-24 HR HR20120108T patent/HRP20120108T2/hr unknown
- 2006-05-24 EA EA200702612A patent/EA013240B1/ru not_active IP Right Cessation
- 2006-05-24 PL PL06760341T patent/PL1899324T3/pl unknown
- 2006-05-24 NZ NZ563068A patent/NZ563068A/en not_active IP Right Cessation
- 2006-05-24 AU AU2006250009A patent/AU2006250009B2/en not_active Ceased
- 2006-05-24 WO PCT/US2006/020085 patent/WO2006127815A2/en not_active Ceased
- 2006-05-24 CA CA2607280A patent/CA2607280C/en not_active Expired - Lifetime
- 2006-05-24 ES ES06760341T patent/ES2376115T3/es not_active Expired - Lifetime
- 2006-05-24 US US11/920,817 patent/US8143279B2/en not_active Expired - Fee Related
- 2006-05-24 EP EP06760341A patent/EP1899324B1/en not_active Expired - Lifetime
- 2006-05-24 JP JP2008513672A patent/JP5072111B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-24 IL IL186883A patent/IL186883A/en active IP Right Grant
- 2007-12-10 MA MA30466A patent/MA29541B1/fr unknown
- 2007-12-17 NO NO20076481A patent/NO339658B1/no not_active IP Right Cessation
-
2010
- 2010-06-09 US US12/796,902 patent/US8377964B2/en not_active Expired - Fee Related
-
2012
- 2012-02-17 CY CY20121100168T patent/CY1112366T1/el unknown
- 2012-07-23 JP JP2012162692A patent/JP2012197322A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,783 patent/US20130273568A1/en not_active Abandoned
-
2014
- 2014-09-17 US US14/488,520 patent/US9428489B2/en not_active Expired - Fee Related
-
2016
- 2016-07-28 US US15/221,841 patent/US9975877B2/en not_active Expired - Fee Related
-
2018
- 2018-04-19 US US15/956,958 patent/US10233172B2/en not_active Expired - Lifetime
-
2019
- 2019-01-29 US US16/260,984 patent/US10696656B2/en not_active Expired - Fee Related
-
2020
- 2020-05-22 US US16/881,209 patent/US11254655B2/en not_active Expired - Fee Related
-
2022
- 2022-01-12 US US17/573,814 patent/US20220274957A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| PE20071094A1 (es) | Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| EA200700099A1 (ru) | Производные пиридина | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| CL2011002604A1 (es) | Compuestos derivados de n-(cianometil)-4-(sulfonil)pirrolidina-2-carboxamida, inhibidores de catepsina s o l; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, aterosclerosis, aneurismo aortico abdominal, enfermedades arteriales periferica o la nefropatia diabetica. | |
| PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| PE20071251A1 (es) | Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| EA201000881A1 (ru) | Пиридилметил-сульфонамидные соединения | |
| EA200801011A1 (ru) | Производные пиразина как модуляторы натриевых каналов для лечения боли | |
| PE20060585A1 (es) | Derivados de 2-amido-4-feniltiazol como antagonistas de quimiocinas y su preparacion | |
| PE20060554A1 (es) | Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion | |
| RU2008144952A (ru) | Производные аминометилпиридина, их получение и их применение в терапии | |
| PE20030930A1 (es) | Derivados de tiazol como antagonistas del receptor npy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |